Elucid

Elucid is a commercial-stage diagnostics company leveraging AI and machine learning to transform the assessment of cardiovascular disease. Its core technology, PlaqueIQ, provides a non-invasive 'CT Virtual Histology' that quantifies plaque composition with high correlation to pathological gold standards, addressing the critical need to identify high-risk plaque that leads to heart attacks and strokes. With recent broad reimbursement from CMS and a new CPT code, the company is positioned for significant adoption. Elucid is also developing a plaque-derived FFRCT (Fractional Flow Reserve from CT) product to further integrate functional and morphological assessment.

AI/ML-powered CT Virtual Histology platform for non-invasive, histology-validated quantification and characterization of arterial plaque composition from standard CT angiography scans.

Elucid competes in the AI-based cardiac image analysis segment, differentiating itself through direct histology validation of plaque composition. Key competitors include HeartFlow (FFRCT leader), Cleerly (also focused on plaque), and the AI analytics suites of major imaging OEMs (Siemens, GE, Canon). Its reimbursement advantage is a current differentiator.